Effects of Sacubitril Valsartan on Cardiac Function,Myocardial Injury Markers and the Incidence of MACE in Disabled Elderly Patients with Chronic Heart Failure
Objective:To explore the effects of Sacubitril Valsartan on cardiac function,myocardial injury markers and the incidence of major adverse cardiovascular events (MACE) in disabled elderly patients with chronic heart failure (CHF).Method:A total of 90 disabled elderly patients with CHF who were treated in Department of Internal Medicine Ⅲ,Kunming 311 Hospital from January to June 2022 were selected as the study objects,and were divided into observation group and control group by simple randomization method,with 45 cases in each group.The control group was treated with conventional treatment,and the observation group was treated with Sacubitril Valsartan on this basis.The cardiac function[heart rate (HR),cardiac output (CO),left ventricular ejection fraction (LVEF),left ventricular end-systolic diameter (LVESD) and left ventricular end-diastolic diameter (LVEDD)],myocardial injury markers[N-terminal pro-brain natriuretic peptide (NT-proBNP),cardiac troponin Ⅰ (cTnⅠ),procollagen Ⅲ N-terminal peptide (PⅢNP)]and exercise tolerance[6 min walk test (6MWT)]were compared between the two groups before treatment and 6 months after treatment,and the occurrence of MACE in the two groups were recorded.Result:6 months after treatment,CO and LVEF were increased in both groups,those in the observation group were higher than those in the control group,the distance of 6MWT were increased,that in the observation group was longer than that in the control group,LVESD and LVEDD were decreased,those in the observation group were smaller than those in the control group,HR,NT-proBNP,cTnⅠ and PⅢNP were decreased,and those in the observation group were lower than those in the control group,the differences were statistically significant (P<0.05).There was no significant difference in the incidence of MACE between the two groups (P>0.05).Conclusion:Sacubitril Valsartan can significantly improve clinical symptoms and alleviate myocardial injury in disabled elderly patients with CHF.
万方数据
维普
